A combination of ibrutinib and rituximab is more effective and less toxic than standard immunochemotherapy in first line treatment of chronic lymphocytic leukaemia (CLL), a phase 3 trial has shown. Ibrutinib–rituximab treatment was superior to fludarabine–cyclophosphamide–rituximab with respect to progression-free survival (PFS) and overall survival (OS) in a prospective randomised controlled trial involving 529 people ...
Ibrutinib-rituximab superior to chemo-immunotherapy in CLL
By Michael Woodhead
19 Aug 2019